YARS1
Basic information
Region (hg38): 1:32775237-32818031
Previous symbols: [ "YARS" ]
Links
Phenotypes
GenCC
Source:
- Charcot-Marie-Tooth disease dominant intermediate C (Supportive), mode of inheritance: AD
- Charcot-Marie-Tooth disease dominant intermediate C (Strong), mode of inheritance: AD
- neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2 (Strong), mode of inheritance: AR
- Charcot-Marie-Tooth disease (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Neurologic, endocrine, and pancreatic disease, infantile-onset 2 | AR | Audiologic/Otolaryngologic; Endocrine; Gastrointestinal | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; The condition may include multiple endocrine abnormalities, including early-onset hypoglycemia, and awareness may allow prompt diagnosis and medical management; Individuals have been described with varying degrees of hepatic dysfunction, and awareness may allow management of sequelae | Audiologic/Otolaryngologic; Endocrine; Gastrointestinal; Neurologic | 14606043; 16429158; 27633801; 30214071; 30304524; 33490854 |
ClinVar
This is a list of variants' phenotypes submitted to
- Charcot-Marie-Tooth disease (2 variants)
- Charcot-Marie-Tooth disease dominant intermediate C (2 variants)
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2 (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the YARS1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 86 | 90 | ||||
missense | 222 | 237 | ||||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 12 | 13 | ||||
inframe indel | 7 | |||||
splice donor/acceptor (+/-2bp) | 7 | |||||
splice region | 11 | 17 | 28 | |||
non coding | 16 | 71 | 36 | 123 | ||
Total | 3 | 5 | 274 | 162 | 41 |
Highest pathogenic variant AF is 0.00000657
Variants in YARS1
This is a list of pathogenic ClinVar variants found in the YARS1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-32775257-A-G | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Jan 13, 2018) | ||
1-32775300-A-C | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 13, 2018) | ||
1-32775301-T-C | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 13, 2018) | ||
1-32775382-T-G | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Jan 13, 2018) | ||
1-32775442-T-C | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Jan 13, 2018) | ||
1-32775529-CCCTTT-C | Charcot-Marie-Tooth, Intermediate | Likely benign (Jun 14, 2016) | ||
1-32775542-A-G | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 12, 2018) | ||
1-32775582-C-T | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Jan 13, 2018) | ||
1-32775595-C-A | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 13, 2018) | ||
1-32775612-C-T | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Jan 12, 2018) | ||
1-32775672-CTG-C | Charcot-Marie-Tooth, Intermediate | Likely benign (Jun 14, 2016) | ||
1-32775688-T-C | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jun 16, 2018) | ||
1-32775697-T-C | Charcot-Marie-Tooth disease dominant intermediate C | Benign/Likely benign (Dec 13, 2018) | ||
1-32775843-C-T | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 13, 2018) | ||
1-32775875-G-A | Likely benign (Mar 11, 2019) | |||
1-32775960-G-T | Charcot-Marie-Tooth disease dominant intermediate C | Benign (Jan 12, 2018) | ||
1-32775984-G-C | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Sep 17, 2020) | ||
1-32775989-T-C | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Oct 10, 2022) | ||
1-32775991-T-A | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Sep 08, 2021) | ||
1-32775993-C-T | Charcot-Marie-Tooth disease dominant intermediate C | Likely benign (Jan 20, 2024) | ||
1-32775994-C-T | Charcot-Marie-Tooth disease dominant intermediate C • Inborn genetic diseases | Uncertain significance (Jul 07, 2023) | ||
1-32775995-C-T | Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2 | Pathogenic (Jul 08, 2021) | ||
1-32775997-C-A | Charcot-Marie-Tooth disease dominant intermediate C | Uncertain significance (Sep 03, 2023) | ||
1-32775997-C-G | Charcot-Marie-Tooth disease dominant intermediate C • Inborn genetic diseases | Uncertain significance (Sep 07, 2024) | ||
1-32775997-C-T | Uncertain significance (Aug 19, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
YARS1 | protein_coding | protein_coding | ENST00000373477 | 13 | 42915 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00100 | 0.999 | 125720 | 0 | 28 | 125748 | 0.000111 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.14 | 228 | 282 | 0.809 | 0.0000158 | 3449 |
Missense in Polyphen | 82 | 113.76 | 0.72081 | 1452 | ||
Synonymous | -0.852 | 124 | 113 | 1.10 | 0.00000674 | 1037 |
Loss of Function | 3.05 | 10 | 27.2 | 0.368 | 0.00000137 | 354 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000181 | 0.000181 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.0000924 | 0.0000924 |
European (Non-Finnish) | 0.000106 | 0.000105 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.000131 | 0.000131 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr- AMP and then transferred to the acceptor end of tRNA(Tyr). {ECO:0000250}.;
- Disease
- DISEASE: Charcot-Marie-Tooth disease, dominant, intermediate type, C (CMTDIC) [MIM:608323]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type C is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. {ECO:0000269|PubMed:16429158}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human);Phenylalanine and Tyrosine Metabolism;Phenylketonuria;Tyrosinemia Type 3 (TYRO3);Tyrosinemia Type 2 (or Richner-Hanhart syndrome);tRNA Aminoacylation;Translation;Metabolism of proteins;tRNA charging;Cytosolic tRNA aminoacylation
(Consensus)
Recessive Scores
- pRec
- 0.278
Intolerance Scores
- loftool
- 0.674
- rvis_EVS
- -0.2
- rvis_percentile_EVS
- 38.82
Haploinsufficiency Scores
- pHI
- 0.188
- hipred
- Y
- hipred_score
- 0.657
- ghis
- 0.522
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.998
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Yars
- Phenotype
- homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; embryo phenotype;
Gene ontology
- Biological process
- tRNA aminoacylation for protein translation;tyrosyl-tRNA aminoacylation;apoptotic process
- Cellular component
- extracellular space;cytoplasm;cytosol;nuclear body;aminoacyl-tRNA synthetase multienzyme complex;methionyl glutamyl tRNA synthetase complex
- Molecular function
- tRNA binding;RNA binding;tyrosine-tRNA ligase activity;interleukin-8 receptor binding;protein binding;ATP binding